全文获取类型
收费全文 | 1338篇 |
免费 | 98篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 28篇 |
妇产科学 | 37篇 |
基础医学 | 178篇 |
口腔科学 | 34篇 |
临床医学 | 113篇 |
内科学 | 413篇 |
皮肤病学 | 90篇 |
神经病学 | 79篇 |
特种医学 | 24篇 |
外科学 | 114篇 |
综合类 | 2篇 |
预防医学 | 57篇 |
眼科学 | 27篇 |
药学 | 106篇 |
中国医学 | 11篇 |
肿瘤学 | 128篇 |
出版年
2023年 | 8篇 |
2022年 | 24篇 |
2021年 | 49篇 |
2020年 | 29篇 |
2019年 | 31篇 |
2018年 | 42篇 |
2017年 | 36篇 |
2016年 | 35篇 |
2015年 | 39篇 |
2014年 | 53篇 |
2013年 | 60篇 |
2012年 | 78篇 |
2011年 | 92篇 |
2010年 | 52篇 |
2009年 | 33篇 |
2008年 | 70篇 |
2007年 | 75篇 |
2006年 | 57篇 |
2005年 | 77篇 |
2004年 | 75篇 |
2003年 | 54篇 |
2002年 | 60篇 |
2001年 | 23篇 |
2000年 | 24篇 |
1999年 | 17篇 |
1998年 | 10篇 |
1997年 | 5篇 |
1996年 | 9篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1992年 | 32篇 |
1991年 | 15篇 |
1990年 | 16篇 |
1989年 | 20篇 |
1988年 | 12篇 |
1987年 | 11篇 |
1986年 | 15篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1974年 | 12篇 |
1973年 | 5篇 |
1972年 | 5篇 |
1971年 | 6篇 |
1970年 | 3篇 |
1968年 | 4篇 |
1967年 | 6篇 |
排序方式: 共有1443条查询结果,搜索用时 15 毫秒
41.
Yoshifumi Nishi Chika Ogami Yasuhiro Tsuji Hitoshi Kawasuji Harumi Yamada Shin Kawai Ippei Sakamaki Hideto To Yoshihiro Yamamoto 《Journal of infection and chemotherapy》2021,27(2):165-171
IntroductionAims of this study were (a) to assess the development ratio of hyponatremia during treatment with linezolid and (b) to evaluate the relationship between the risk of hyponatremia and linezolid exposure and patient background.MethodClinical data including linezolid serum concentrations and serum sodium values were collected at Toyama University Hospital and Kyorin University Hospital. Data from 89 patients were used for the analysis, and a nadir serum sodium level ≤130 mmol/L during the treatment with linezolid was defined as hyponatremia. Mann-Whitney's U test was used to evaluate the effects of the area under the time-concentration curve (AUC) of linezolid at the nadir sodium level, clinical characteristics (e.g. laboratory data), and baseline serum sodium levels on the development of hyponatremia.ResultsThe hyponatremia was occurred in 21 of 89 patients (23.6%). Data are compared for baseline and nadir serum sodium levels of patients with and without hyponatremia. In both groups, nadir serum sodium levels were significantly different from those of the baseline values (P < 0.05). The values of AUC0-12, accumulated AUC, baseline serum sodium levels and age were significantly different between patients with and without hyponatremia (P < 0.05).ConclusionsLinezolid exposure, age, and baseline sodium levels were detected as the risk factors for linezolid-related hyponatremia. Our findings suggest that regular monitoring of serum sodium levels is desirable during treatment with linezolid, especially for the elderly and patients with low serum sodium levels before the start of linezolid administration. 相似文献
42.
Nakamura T Kawagoe Y Matsuda T Ueda Y Ebihara I Koide H 《Diabetes/metabolism research and reviews》2005,21(1):39-43
BACKGROUND: To determine whether diabetic nephropathy is a risk factor for silent cerebral infarction and whether antiplatelet drug dilazep dihydrochloride decreases the occurrence of silent cerebral infarction in type 2 diabetes patients with microalbuminuria. METHODS: Two hundred four type 2 diabetes patients (124 men, 80 women; age, median 56 years, range 42-74 years) and 60 healthy age-matched subjects (no diabetes, normal renal function) were recruited for brain magnetic resonance imaging. The diabetes patients included 40 without nephropathy (group A), 42 with microalbuminuria (20-200 microg/min) (group B), 44 with macroalbuminuria (>200 microg/min) and normal renal function (blood creatinine <132.7 micromol/L) (group C), 33 with chronic renal failure but not undergoing haemodialysis (blood creatinine >132.7 micromol/L; mean creatinine 335.9 micromol/L) (group D) and 45 undergoing haemodialysis (duration; median 4 years, range 3-6 years) (group E). RESULTS: Silent cerebral infarction was found in 20, 29, 34, 45, 53 and 8% of group A, B, C, D, E and control patients respectively. The incidence of silent cerebral infarction was increased with diabetic nephropathy. Thirty group B patients with no silent cerebral infarction were divided into two groups: (B1) 15 treated with dilazep dihydrochloride and (B2) 15 not treated with dilazep dihydrochloride. Treatment continued for 24 months. The incidence of silent cerebral infarction was significantly lower in the dilazep-treated patients (6.7%) than in the untreated patients (33.3%) (p < 0.01). CONCLUSIONS: These data suggest that diabetic renal dysfunction increases the risk of silent cerebral infarction and that dilazep dihydrochloride prevents its onset in early type 2 diabetic nephropathy patients. 相似文献
43.
44.
Miyake Y Ohnishi M Fujii TK Yamamoto T Yoneda C Takahashi S Ichimaru Y 《Clinical and experimental hypertension (New York, N.Y. : 1993)》2002,24(1-2):23-31
In order to understand the changes of baroreflex gain due to postural changes in normal pregnancies, we measured percentage changes (% changes) in blood pressure (SBP, DBP), heart rate (HR), stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR) as well as cardiac autonomic nervous function (HF as an index of parasympathetic and LF/HF as an index of sympathetic function) and compared these parameters in normal pregnancies with those found in hypertensive pregnancies, such as chronic hypertensive (CHP) and severe preeclamptic pregnancies (PE), in late pregnancy (after 32 wks). When the position was changed from supine to standing in normal and non-pregnant women, the % changes of HR, DBP, TPR and LF/HF were increased and SBP, SV, CO and HF were decreased. The % changes of these parameters, however, were gradually decreased as pregnancy progressed, especially after 20-24 wks of gestation. In hypertensive pregnancies, however, even in late pregnancy, the decreased SBP and increased TPR was still observed and the profound decrease of CO and SV and increase of TPR were characteristic in PE when compared to CHP. 相似文献
45.
46.
S Futagami M Shimpuku JM Song Y Kodaka H Yamawaki H Nagoya T Shindo T Kawagoe A Horie K Gudis K Iwakiri C Sakamoto 《Digestion》2012,86(2):114-121
Background/Aims: In this crossover study, we investigated whether nizatidine, a H(2)-receptor antagonist, can alleviate clinical symptoms and gastric emptying in patients with Rome III-based functional dyspepsia (FD) with or without impaired gastric emptying. Methods: We enrolled 30 patients presenting with FD symptoms (epigastric pain syndrome, n = 6; postprandial distress syndrome, n = 24). Rome III-based FD patients were treated with nizatidine (300 mg/day) or placebo for 4 weeks in a crossover trial. Gastric motility was mainly evaluated with the T(max) value using the (13)C-acetate breath test. Meal-related symptoms were defined as postprandial fullness and early satiation. Gastroesophageal symptom was defined as a burning feeling rising from the stomach or lower chest up toward the neck. Acylated- and desacylated ghrelin levels were evaluated by the ELISA method. Clinical symptoms, gastric emptying and ghrelin levels were evaluated at three different points during the study (pretreatment, after 4 weeks former treatment and after 4 weeks later treatment). The primary end point of this study was to determine whether nizatidine would improve clinical symptoms and gastric emptying in FD patients with or without impaired gastric emptying via affecting ghrelin levels. Results: Meal-related symptoms of the patients treated with nizatidine improved significantly (21/30; 70%) compared to those treated with placebo (3/30; 10%). In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with placebo (0/30; 0%). Nizatidine treatment in patients with FD accompanied by impaired gastric emptying significantly improved clinical symptoms and T(max) value as a marker of gastric emptying (10/11, 91%; 9/11, 82%) compared to placebo therapy, respectively. There were no significant differences in ghrelin levels between nizatidine treatment and placebo therapy. Conclusion: Nizatidine administration significantly improved both gastric emptying and clinical symptoms in FD patients with impaired gastric emptying. 相似文献
47.
48.
49.
50.